Sex: F
Vaccine: MMR
Symptoms: Parotid gland enlargement, Polymerase chain reaction positive, Pyrexia, Salivary gland enlargement, Viral titre
Clinical narrative: These results suggest that symptomatic cases do not have protective levels of antibodies to JL and genotype G prior to mumps infection; This literature marketed report had been received from the authors of a published article, titled as stated above, and refers to a 20-year-old female patient. The article aimed that in 2017, a mumps outbreak occurred in a group setting, so serum collected at entry was used to compare pre-exposure with presumptive vaccine-induced antibody levels from persons who developed mumps (cases) and potentially exposed persons who did not develop mumps (non-cases).  Information regarding the patient's pertinent medical history, concurrent conditions, concomitant therapies and previous drug reactions or allergies was not provided.  On an unknown date, the patient was vaccinated with 2 dose childhood regimen of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown) as prophylaxis (dose, route of administration, vaccination scheme frequency, anatomical location, lot number and expiration date were not reported).  On 10-AUG-2016, a sample was collected and showed Jeryl Lynn (JL) titer at 8.6 (units not provided) and genotype G titer at 8.6 (units not provided), CDC IgM was negative (-), Zeus IgG was negative (-) (Zeus Index value: 0.74 (units not provided)), avidity was not tested. On 22-NOV-2016, a sample was collected and showed JL titer at 6.2 (units not provided) and genotype G titer at 5.5 (units not provided), CDC IgM was negative (-), Zeus IgG was negative (-) (Zeus Index value: 0.80 (units not provided)), avidity was not tested. It was reported that results suggested that symptomatic cases do not have protective levels of antibodies to JL and genotype G prior to mumps infection (mumps antibody test negative).  On 20-APR-2017, the patient received outbreak dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown)) (dose, route of administration, anatomical location, lot number and expiration date were not reported).  On 23-APR-2017, the patient was symptomatic and exhibited typical mumps symptoms (parotid/salivary gland swelling, orchitis, fever, malaise)..   On 26-APR-2017, CDC laboratory classification reported confirmed case (C) of mumps. Also, sample collected show JL titer at 30.6 (units not provided) and genotype G titer at 10.1 (units not provided), CDC IgM was indetermined (IND), Zeus IgG was positive (+) (Zeus Index value: 2.84 (units not provided)), avidity was  51 percent (High), and PCR was positive. Other testing and alternative diagnosis were negative rhinovirus (rhino) and mononucleosis spot test (monospot).   The outcome of the event mumps antibody test negative was not provided. The causal relationship between the event mumps antibody test negative and the suspect therapy measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown) was considered as related.  Lot # is being requested and will be submitted if received.  This is one of several reports received from the literature.  A copy of the published article is attached as further documentation of the patient's experience.  Sender's Comments:  US-009507513-2408USA003357: US-009507513-2408USA003354: US-009507513-2407USA014510: US-009507513-2408USA003353: US-009507513-2408USA003358: US-009507513-2408USA003363: US-009507513-2408USA003362: US-009507513-2408USA003361: US-009507513-2408USA003355: US-009507513-2408USA003356: US-009507513-2408USA003360: